Payment overview · 2025
General Payments
$1,405.55
68 reported records · 18 companies
Healthcare provider profile · identity verified
Scott Nesbitt, MD
Allopathic & Osteopathic Physicians|Family Medicine · BUTLER, PA · NPI 1962419861
Verified facts
What the public records show
CMS Open Payments records show Scott Nesbitt, MD received $1,405.55 in general payments during 2025 across 68 reported records.
Lilly USA, LLC accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $252.62 | 18.0% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $192.58 | 13.7% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $168.76 | 12.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $166.45 | 11.8% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $156.83 | 11.2% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $87.80 | 6.2% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.04 | 5.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.70 | 4.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.05 | 3.1% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $40.04 | 2.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $24.85 | 1.8% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $24.69 | 1.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $23.47 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.64 | 1.5% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $19.88 | 1.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.03 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.02 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.10 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,395.55 | 67 |
| Education | $10.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $192.58 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $156.83 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $136.61 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.29 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $116.01 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.85 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $91.61 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $87.80 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.02 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.24 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $70.04 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.47 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.41 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.05 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $40.04 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.64 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
126 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 304 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 284 | 57 |
| Atorvastatin Calcium | Atorvastatin Calcium | 275 | 83 |
| Simvastatin | Simvastatin | 262 | 73 |
| Omeprazole | Omeprazole | 253 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 68 |
| Lorazepam | Lorazepam | 214 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 184 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 49 |
| Sertraline Hcl | Sertraline Hcl | 147 | 32 |
| Prednisone | Prednisone | 144 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 38 |
| Ezetimibe | Ezetimibe | 139 | 40 |
| Synthroid | Levothyroxine Sodium | 126 | 27 |
| Meloxicam | Meloxicam | 120 | 26 |
| Ozempic | Semaglutide | 115 | 21 |
| Irbesartan | Irbesartan | 114 | 27 |
| Furosemide | Furosemide | 98 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 97 | 29 |
| Gabapentin | Gabapentin | 94 | 14 |
| Potassium Chloride | Potassium Chloride | 94 | 27 |
| Metformin Hcl Er | Metformin Hcl | 88 | 23 |
| Eliquis | Apixaban | 85 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 80 | 21 |
| Montelukast Sodium | Montelukast Sodium | 75 | 17 |
| Celecoxib | Celecoxib | 71 | 20 |
| Donepezil Hcl | Donepezil Hcl | 71 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 69 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 66 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 18 |
| Jardiance | Empagliflozin | 61 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 13 |
| Allopurinol | Allopurinol | 53 | 14 |
| Metformin Hcl | Metformin Hcl | 50 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 12 |
| Atenolol | Atenolol | 45 | 11 |
| Glipizide | Glipizide | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 45 | suppressed |
| Losartan Potassium | Losartan Potassium | 44 | 13 |
| Alprazolam | Alprazolam | 42 | suppressed |
| Clonazepam | Clonazepam | 42 | 13 |
| Valsartan | Valsartan | 41 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 14 |
| Famotidine | Famotidine | 38 | 16 |
| Trulicity | Dulaglutide | 38 | 11 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 14 |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 36 | 11 |
| Glimepiride | Glimepiride | 34 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | 11 |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 20 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 27 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 20 |
| Azithromycin | Azithromycin | 21 | 17 |
| Cephalexin | Cephalexin | 21 | 16 |
| Finasteride | Finasteride | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 15 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Livalo | Pitavastatin Calcium | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 11 |
| Baclofen | Baclofen | 13 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,405.55 · 68 records | Lilly USA, LLC | AIRSUPRA, Auvelity, BREZTRI, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE 3, Flector, GARDASIL 9, JARDIANCE, Licart, MOUNJARO, NEXLETOL, NUZYRA, Ozempic, QULIPTA, Quviviq, REPATHA, Rybelsus, TRELEGY ELLIPTA, Tirosint, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error